SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-358273"
 

Sökning: id:"swepub:oai:DiVA.org:uu-358273" > Introduction of the...

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C : a register-based study in Sweden

Frisk, Pia (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Stockholm Cty Council, Publ Healthcare Serv Comm, POB 6909, S-10239 Stockholm, Sweden
Aggefors, K. (författare)
Stockholm Cty Council, Publ Healthcare Serv Comm, POB 6909, S-10239 Stockholm, Sweden
Cars, Thomas (författare)
Uppsala universitet,Kardiovaskulär epidemiologi
visa fler...
Feltelius, N. (författare)
Med Prod Agcy, Uppsala, Sweden
Loov, S. A. (författare)
Stockholm Cty Council, Publ Healthcare Serv Comm, POB 6909, S-10239 Stockholm, Sweden
Wettermark, B. (författare)
Karolinska Institutet
Weiland, O. (författare)
Karolinska Institutet
visa färre...
 (creator_code:org_t)
2018-04-09
2018
Engelska.
Ingår i: European Journal of Clinical Pharmacology. - : SPRINGER HEIDELBERG. - 0031-6970 .- 1432-1041. ; 74:7, s. 971-978
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Introduction of the direct-acting antivirals (DAAs) for treatment of chronic hepatitis C (CHC) infection has been challenging in all health systems. In Sweden, a national protocol for managed introduction was developed. It was optional, but all county councils agreed to implement and follow it. The purpose of this study was to study (a) cure rates among all patients initiated on treatment in 2014-2015, (b) prescribers' adherence to the drug recommendations and treatment eligibility criteria in the protocol, and (c) introduction rate in the six Swedish healthcare regions. A cross-sectional study where national data from the Prescribed Drug Register and the quality register InfCare Hepatitis defined the study population, and clinical data from the Patient Register and InfCare Hepatitis were used to monitor outcomes. Descriptive statistics were used. A total of 3447 patients were initiated on treatment during 2014-2015. The overall cure rate, based on data from 85% of the cohort, was 96%, with variation between genotypes. Adherence to drug recommendations increased over time and varied between 43.2 and 94.2%. Adherence to the treatment eligibility criteria was initially 80% and increased to 87% when treatment restrictions were widened. The introduction rate differed initially between the regions and reached stable levels 15-18 months after the launch of the first DAA. The estimated overall cure rate was 96%, with some variations between genotypes. A high level of adherence to the introduction protocol as well as similar introduction rates in the health care regions indicate that the introduction protocol, alongside with other measures taken, contributed considerably to a rapid uptake and equal distribution of DAAs in Sweden.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Nyckelord

Hepatitis C
Direct-acting antivirals
Effectiveness
Managed introduction

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy